Oncolytics Biotech (ONCY) Research & Development (2009 - 2026)

Oncolytics Biotech (ONCY) has reported Research & Development for 18 consecutive years, with $4.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 122.44% year-over-year to $4.3 million in Q2 2026; TTM through Jun 2026 was $14.5 million, a 11.41% increase from a year earlier, with the FY2025 full-year figure at $13.3 million, down 13.79% from the prior year.
• Research & Development was $4.3 million for Q2 2026 at Oncolytics Biotech, down from $5.5 million in the prior quarter.
• Over five years, Research & Development peaked at $5.5 million in Q3 2025 and troughed at $1.9 million in Q2 2025.
• A 5-year average of $3.5 million and a median of $3.3 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development sank 42.51% in 2025 and jumped 122.44% in 2026, its largest moves.
• Over 5 years, Research & Development stood at $3.6 million in 2022, then fell by 4.06% to $3.4 million in 2023, then declined by 4.76% to $3.3 million in 2024, then jumped by 67.58% to $5.5 million in 2025, then decreased by 21.95% to $4.3 million in 2026.
• The last three Research & Development figures came in at $4.3 million (Q2 2026), $5.5 million (Q3 2025), and $1.9 million (Q2 2025), per Business Quant data.